Table 1 Characteristics of stage I patients with ENPG and IMRT

Gender

0.466*

 Female

3 (30.0)

72 (21.9)

 Male

7 (70.0)

257 (78.1)

Age [median + SD (range)]

47.0 ± 14.5 (29–73)

45.0 ± 10.9 (19–75)

0.480^#

BMI [mean + SD (range)]

24.4 ± 2.7 (18.8–27.9)

23.2 ± 3.0 (15.6–33.4)

0.129^#

Karnofsky performance status

0.215*

 ≥ 90

9 (90.0)

322 (97.9)

 < 90

1 (10.0)

7 (2.1)

Clinical stage

–

 I

10 (100.0)

329 (100.0)

 II

0

0

 III

0

0

 IV

0

0

Histology

0.306*

 WHO I

0

0

 WHO II

1 (10.0)

11 (3.3)

 WHO III

9 (90.0)

318 (96.7)

Smoking history

0.461*

 Yes

1 (10.0)

84 (25.5)

 No

9 (90.0)

245 (74.5)

Total doses [mean + SD (range)]

–

68.85 ± 1.24 (66.00–70.29)

–

Fractionated dose [mean + SD (range)]

–

2.24 ± 0.08 (2.00–2.36)

–

Reconstruction

–

–

 Yes

6 (60.0)

–

 No

4 (40.0)

–